Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Phase 1 Terminated
115 enrolled 43 charts
EV-103
Phase 1/2 Terminated
348 enrolled 2 FDA
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
Phase 1/2 Terminated
19 enrolled 11 charts
TEM-GU
Phase 1/2 Terminated
10 enrolled
Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma
Phase 1/2 Terminated
4 enrolled 8 charts
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
61 enrolled 29 charts
Futibatinib and Pembrolizumab Combination in the Treatment of Advanced or Metastatic Urothelial Carcinoma
Phase 2 Terminated
43 enrolled 15 charts
Aldesleukin and Pembrolizumab in Treating Patients With Advanced or Metastatic Kidney Cancer
Phase 1 Terminated
6 enrolled 11 charts
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Phase 2 Terminated
18 enrolled
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
Phase 2 Terminated
6 enrolled 11 charts
Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205)
Phase 2 Terminated
7 enrolled 10 charts
Study of PULSAR-ICI +/- IMSA101 in Patients With Oligometastatic NSCLC and RCC
Phase 2 Terminated
6 enrolled 7 charts
Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
Phase 1 Terminated
212 enrolled
Immunotherapy With or Without Radiation Therapy for Metastatic Urothelial Cancer
Phase 2 Terminated
1 enrolled 1 chart
Trial of LAVA-1207 in Patients With Therapy Refractory Metastatic Castration Resistant Prostate Cancer (mCRPC) Resistant Prostate Cancer
Phase 1 Terminated
96 enrolled
NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours
Phase 1/2 Terminated
19 enrolled
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
Phase 1 Terminated
221 enrolled
RAPTOR
Phase 1 Terminated
27 enrolled
Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)
Phase 2 Terminated
11 enrolled 16 charts
A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors
Phase 2 Terminated
205 enrolled 54 charts
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
Phase 2 Terminated
4 enrolled 10 charts
Neutron Radiation Therapy and Pembrolizumab in Treating Participants With Advanced Urothelial Carcinoma
Phase 2 Terminated
12 enrolled 10 charts
PDL1x41BB
Phase 1 Terminated
160 enrolled
KEYNOTE-921
Phase 3 Terminated
81 enrolled 19 charts
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
Phase 1 Terminated
78 enrolled 39 charts
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
47 enrolled 11 charts
A Study of PY314 in Subjects With Advanced Solid Tumors
Phase 1 Terminated
86 enrolled
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial
Phase 1 Terminated
2 enrolled
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Phase 1 Terminated
87 enrolled
TORCH
Phase 1 Terminated
10 enrolled
A Phase 2 Study of Sitravatinib in Combination With PD-(L)1 Checkpoint Inhibitor Regimens in Patients With Advanced or Metastatic Urothelial Carcinoma
Phase 2 Terminated
260 enrolled 28 charts
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors
Phase 1/2 Terminated
63 enrolled
NEO
Phase 1 Terminated
13 enrolled
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Phase 1 Terminated
61 enrolled
Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors
Phase 2 Terminated
12 enrolled 14 charts
Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer
Phase 2 Terminated
21 enrolled 12 charts
Trial of Pembrolizumab for Advanced Penile Squamous Cell Carcinoma
Phase 2 Terminated
6 enrolled 10 charts
Anti-PD(L)1 and SBRT in the Treatment of Advanced, Platinum-Refractory Urothelial Carcinoma
Phase 2 Terminated
6 enrolled 11 charts
A Phase II Randomized Trial of Immunotherapy Plus Radiotherapy in Metastatic Genitourinary Cancers
Phase 2 Terminated
6 enrolled 12 charts
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
MK-6018-001
Phase 1 Terminated
27 enrolled
PemBla
Phase 1/2 Terminated
6 enrolled 12 charts
MK-3475-031
Phase 1 Terminated
10 enrolled 13 charts
APPEASE
Phase 1 Terminated
5 enrolled
A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of INCB001158 Plus Epacadostat, With or Without Pembrolizumab, in Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled 4 charts
FIERCE-22
Phase 1/2 Terminated
28 enrolled 8 charts
A Safety Study of SGN-2FF for Patients With Advanced Solid Tumors
Phase 1 Terminated
47 enrolled
Ph 1B B-701 in Combination With Pembrolizumab in Metastatic Transitional Cell Carcinoma of the Urothelial Tract
Phase 1 Terminated
1 enrolled